Decision makers need an approach to determine digital therapeutic product quality, access, and appropriate use

Abstract

DISCLOSURES: No funding was received for the writing of this article. Parcher is employed by Xcenda and has nothing to disclose. Coder is employed by Digital Therapeutics Alliance, which is a member of the USP Convention. Coder reports fees from PsychU/Otsuka.